United States - English - NLM (National Library of Medicine)

putney, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

darmerica - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 1 kg in 1 kg

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 5 kg in 5 kg

United States - English - NLM (National Library of Medicine)

professional group of pharmacists new york llc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

United States - English - NLM (National Library of Medicine)

darmerica - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

United States - English - NLM (National Library of Medicine)

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

zyvet animal health inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), silver sulfadiazine (unii: w46jy43ejr) (sulfadiazine - unii:0n7609k889) - enrofloxacin 5 mg in 1 ml - baytril® otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine (see microbiology section). baytril® otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides.

United States - English - NLM (National Library of Medicine)

virbac ah, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle - single-dose therapy: tenotryl™ is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis. cattle - multiple-day therapy: tenotryl™ is indicated forthe treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle.  swine: tenotryl™ is indicated for the treatment and controlof swine respiratory disease (srd) associated with actinobacilluspleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae. tenotryl™ is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacil

United States - English - NLM (National Library of Medicine)

putney, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg in 1 ml